{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:03:41Z","timestamp":1789499021991,"version":"build-2803163510"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"26","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"\u00e9\u2021\u008d\u00e5\u00ba\u2020\u00e5\u00b8\u201a\u00e8\u008d\u00a3\u00e6\u02dc\u0152\u00e5\u0152\u00ba\u00e4\u00ba\u00ba\u00e6\u00b0\u2018\u00e5\u0152\u00bb\u00e9\u2122\u00a2","award":["202208-RC"],"award-info":[{"award-number":["202208-RC"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,26]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>This study aimed to explore the efficacy of combining high\u2011flux hemodialysis (HFHD) with a hypoxia\u2011inducible factor prolyl hydroxylase inhibitor (HIF-PHI) for the treatment of renal anemia among patients with end-stage kidney disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Sixty-four newly treated maintenance hemodialysis (MHD) patients were allocated to 4 groups (n\u2005=\u200516 each): low-flux hemodialysis (LFHD) plus recombinant human erythropoietin (rhEPO), LFHD plus HIF-PHI, HFHD plus rhEPO, and HFHD plus HIF\u2011PHI. All patients underwent hemodialysis 3 times per week, each session lasting 4 hours. After 2 months of treatment, we measured and compared changes in hemoglobin (HB), red blood cells (RBC), hepcidin, total iron\u2011binding capacity (TIBC), ferritin, transferrin saturation (TSAT), parathyroid hormone (PTH), and \u03b2\n                      <jats:sub>2<\/jats:sub>\n                      -microglobulin (\u03b2\n                      <jats:sub>2<\/jats:sub>\n                      -MG), along with the incidence of adverse events in each group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      All groups showed increases in HB and RBC post\u2011treatment (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;.05). The increases in hemoglobin (\u0394HB) and RBC (\u0394RBC) were significantly greater in the HFHD\u2005+\u2005HIF-PHI and LFHD\u2005+\u2005HIF-PHI groups than in the LFHD\u2005+\u2005rhEPO and HFHD\u2005+\u2005rhEPO groups. Posttreatment PTH and \u03b2\n                      <jats:sub>2<\/jats:sub>\n                      -MG levels were elevated in the LFHD\u2005+\u2005rhEPO and LFHD\u2005+\u2005HIF-PHI groups compared with pretreatment (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;.05). Furthermore, posttreatment PTH and \u03b2\n                      <jats:sub>2<\/jats:sub>\n                      -MG were lower in the HFHD\u2005+\u2005HIF-PHI and HFHD\u2005+\u2005rhEPO groups than in the other 2 groups (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;.05). Posttreatment hepcidin was significantly reduced in the HFHD\u2005+\u2005HIF-PHI and LFHD\u2005+\u2005HIF-PHI groups compared to pretreatment. Posttreatment TIBC and TSAT were higher in the HFHD\u2005+\u2005HIF-PHI and LFHD\u2005+\u2005HIF-PHI groups than pretreatment (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;.05). The incidence of adverse reactions was numerically lower in the HIF-PHI groups than in the rhEPO group, but the difference was not statistically significant.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Compared to low-flux dialysis plus rhEPO, the combination of HFHD and HIF-PHI shows more favorable improvements in hemoglobin levels, iron metabolism markers, and clearance of middle-molecule toxins in patients with incident MHD. However, the safety profile requires further evaluation in larger trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000049445","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T18:01:54Z","timestamp":1782496914000},"page":"e49445","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Application of high-flux hemodialysis combined with hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of renal anemia in patients with uremia: A randomized controlled trial"],"prefix":"10.1097","volume":"105","author":[{"given":"Jiajia","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, The People\u2019s Hospital of Rongchang District, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anming","family":"Gong","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The People\u2019s Hospital of Rongchang District, Chongqing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yurun","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The People\u2019s Hospital of Rongchang District, Chongqing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengjuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The People\u2019s Hospital of Rongchang District, Chongqing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0606-4573","authenticated-orcid":false,"given":"Jiguang","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The People\u2019s Hospital of Rongchang District, Chongqing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260915","doi-asserted-by":"crossref","first-page":"151471","DOI":"10.1016\/j.semnephrol.2023.151471","article-title":"COVID and the kidney: an update.","volume":"43","author":"Bell","year":"2023","journal-title":"Semin Nephrol"},{"key":"R2-20260915","doi-asserted-by":"crossref","first-page":"e0009156","DOI":"10.1371\/journal.pntd.0009156","article-title":"Covid-19 in end-stage renal disease patients with renal replacement therapies: a systematic review and meta-analysis.","volume":"15","author":"Nopsopon","year":"2021","journal-title":"PLoS NeglTrop Dis"},{"key":"R3-20260915","doi-asserted-by":"crossref","first-page":"725","DOI":"10.3390\/ijms21030725","article-title":"The influence of inflammation on anemia in CKD patients.","volume":"21","author":"Gluba-Brzozka","year":"2020","journal-title":"Int J Mol Sci"},{"key":"R4-20260915","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1053\/j.ajkd.2017.09.026","article-title":"Update on anemia in ESRD and earlier stages of CKD: core curriculum 2018.","volume":"71","author":"Fishbane","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"R5-20260915","doi-asserted-by":"crossref","first-page":"849","DOI":"10.2174\/09298673113206660270","article-title":"Does erythropoietin always win?","volume":"21","author":"Cernaro","year":"2014","journal-title":"Curr Med Chem"},{"key":"R6-20260915","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2011111078","article-title":"Mechanisms of anemia in CKD.","volume":"23","author":"Babitt","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"R7-20260915","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1053\/j.ajkd.2006.04.023","article-title":"KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease - foreword.","volume":"47","author":"Levin","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"R8-20260915","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1053\/j.jrn.2020.03.004","article-title":"Evolution of treatment for anemia in chronic kidney disease.","volume":"30","author":"Vaught","year":"2020","journal-title":"J Ren Nutr"},{"key":"R9-20260915","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1159\/000548711","article-title":"Comparative effectiveness and safety of roxadustat versus erythropoiesis-stimulating agents in patients receiving maintenance hemodialysis: a real-world cohort study.","volume":"11","author":"Zhang","year":"2025","journal-title":"Kidney Dis (Basel)"},{"key":"R10-20260915","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa2113380","article-title":"Daprodustat for the treatment of anemia in patients not undergoing dialysis.","volume":"385","author":"Singh","year":"2021","journal-title":"N Engl J Med"},{"key":"R11-20260915","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1093\/ndt\/gfab051","article-title":"Roxadustat for anemia in patients with end-stage renal disease incident to dialysis.","volume":"36","author":"Provenzano","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"R12-20260915","first-page":"CD005016","article-title":"High-flux versus low-flux membranes for end-stage kidney disease.","volume":"2012","author":"Palmer","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"R13-20260915","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/joneph\/17.5.701","article-title":"The effect of high-flux hemodialysis on renal anemia.","volume":"17","author":"Ayli","year":"2004","journal-title":"J Nephrol"},{"key":"R14-20260915","doi-asserted-by":"crossref","first-page":"e0128079","DOI":"10.1371\/journal.pone.0128079","article-title":"Effect of high-flux dialysis on circulating FGF-23 levels in end-stage renal disease patients: results from a randomized trial.","volume":"10","author":"Schneider","year":"2015","journal-title":"PLoS One"},{"key":"R15-20260915","first-page":"388","article-title":"Survival benefit of hemodiafiltration compared with prolonged high-flux hemodialysis.","volume":"10","author":"Djuric","year":"2016","journal-title":"Iran J Kidney Dis"},{"key":"R16-20260915","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1681\/ASN.2019020213","article-title":"Iron deficiency in chronic kidney disease: updates on pathophysiology, diagnosis, and treatment.","volume":"31","author":"Batchelor","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"R17-20260915","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.3390\/jcm8091382","article-title":"Chronic use of proton-pump inhibitors and iron status in renal transplant recipients.","volume":"8","author":"Douwes","year":"2019","journal-title":"J Clin Med"},{"key":"R18-20260915","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000496492","article-title":"Iron deficiency anemia in chronic kidney disease.","volume":"142","author":"Gaiter-Gvili","year":"2019","journal-title":"Acta Haematol"},{"key":"R19-20260915","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1681\/ASN.2019060623","article-title":"Phase 3, randomized, double-blind, active-comparator (darbepoetin alfa) study of oral roxadustat in CKD patients with anemia on hemodialysis in Japan.","volume":"31","author":"Akizawa","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"R20-20260915","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa1901713","article-title":"Roxadustat treatment for anemia in patients undergoing long-term dialysis.","volume":"381","author":"Chen","year":"2019","journal-title":"N Engl J Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000049445","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:10:32Z","timestamp":1789495832000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000049445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":20,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000049445","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"assertion":[{"value":"2024-12-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-07","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}